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Abstract
Background: The aim of the study was to reassess the prevalence and characteristics of human T lymphotropic
virus type I (HTLV-I)-associated Sjögren’s syndrome (SS) and SS in HTLV-I-associated myelopathy (HAM) based on
the American European Consensus Group (AECG) criteria in HTLV-I endemic area, Nagasaki prefecture.
Methods: The 349 patients who underwent a minor salivary gland biopsy (MSGB) for suspected SS were
retrospectively classified by AECG classification criteria and divided with or without anti-HTLV-I antibody.
Results: The HTLV-I data-available 294 patients were investigated. One hundred-seventy patients were classified as SS
and 26.5 % were HTLV-I-seropositive. We have included 26 patients with HTLV-I-associated myelopathy (HAM) and
38.5 % were classified as having SS. The prevalences of ANA and anti-SS-A/Ro antibody of HAM + SS were significantly
low compared to the HTLV-I asymptomatic carriers (AC) with SS and the HTLV-I-seronegative SS patients, although
lacrimal dysfunction tended to be high in HAM+ SS and significantly high in AC + SS patients compared with the
patients with HTLV-I-seronegative SS. The focus scores of MSGB in the HAM+ SS patients were similar to those of the
AC + SS patients and the HTLV-I-seronegative patients with SS. Among the MSGB-positive patients, there was a low
prevalence of ANA in the HAM + SS patients. Similar results were obtained in case of anti-SS-A/Ro or SS-B/La antibody.
Conclusion: In HTLV-I endemic area, high prevalence of anti-HTLV-I antibody among SS as well as the characteristics of
HAM+ SS and AC + SS was still determined by AECG classification criteria.
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Background
Human T lymphotropic virus type I (HTLV-I), one of the
human retroviruses, is known to be a causative agent of
HTLV-I-associated myelopathy (HAM)/tropical spastic
paraparesis (TSP) and adult-T cell leukemia (ATL) [1, 2].
Sjögren’s syndrome (SS) is an autoimmune disorder char-
acterized by sicca symptoms due to mononuclear cell
(MNC) infiltration into the salivary glands or lacrimal
glands [3–5]. The association between HTLV-I and SS
was discussed in the 1990s, and epidemiological evidence
of the association has been published [6–9]. We also re-
ported a high prevalence of SS among individuals with
HAM [10, 11], which strongly supports the idea that
HTLV-I is involved in the pathogenesis of SS in a subset
of SS patients in HTLV-I endemic areas.
However, we should note that the diagnosis of SS in the
1990s was performed using the Preliminary European
classification criteria [12] published in 1993 (the prelimin-
ary classification criteria). These criteria consist of six
items, and the diagnosis of primary SS (pSS) is determined
by the presence of four of the six items. The classification
criteria released in 2002 by the American European
Consensus Group (AECG; i.e., the AECG classification
criteria) [13] are now used to classify pSS and secondary
SS (sSS). The AECG classification criteria [12] have
revised rules to classify primary SS: namely, positive histo-
pathology or serology is necessary when all six items are
factors for classification. However, the presence of three
items among four objective items also allows the
* Correspondence: nakamura_hideki911@yahoo.co.jp
1Unit of Translational Medicine, Department of Immunology and
Rheumatology, Nagasaki University Graduate School of Biomedical Sciences,
1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501, Japan
Full list of author information is available at the end of the article
© 2015 Nakamura et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nakamura et al. BMC Musculoskeletal Disorders  (2015) 16:335 
DOI 10.1186/s12891-015-0773-1
classification of a patient as having primary SS. In
addition, the newly proposed American College of
Rheumatology (ACR) classification criteria [14] provide a
simpler diagnostic method because a minimum of two out
of three items is sufficient for the diagnosis of SS.
In our previous studies [10, 11], the exocrine dysfunc-
tion of the patients with SS was similar regardless of
HTLV-I infection. However, the prevalence of anti-
nuclear antibody (ANA) and anti-SS-A/Ro, SS-B/La
antibodies of HAM patients with SS was lower than that
of asymptomatic HTLV-I carriers (ACs) with SS and
HTLV-I-seronegative SS when the preliminary criteria
were used. We therefore reevaluated the suspected SS
patients by using the AECG classification criteria. Al-
though this historical cohort study was conducted retro-
spectively with cases from a single center in an HTLV-I
endemic area, i.e., Nagasaki prefecture in Japan, our
findings can provide a current perspective with regard to




We enrolled 349 patients who underwent a minor salivary
gland biopsy (MSGB) for suspected SS between 1995 and
2015 at Nagasaki University Hospital. The availability of
data regarding ocular signs including Rose-Bengal staining
and fluorescein testing results was too low to use the ACR
classification criteria [13] released in 2012, and therefore
we used the AECG classification criteria [12]. The classifi-
cations of pSS and sSS were accomplished in accord with
the revised rule in the AECG criteria, respectively.
In accord with the AECG exclusion criteria, we ex-
cluded all cases that involved radiation treatment, evi-
dent hepatitis induced by hepatitis type C, acquired
immunodeficiency disease, lymphoma, sarcoidosis, graft
versus host disease, or the use of anticholinergic drugs.
Among the 349 patients, 294 patients had available data
for anti-HTLV-I antibody (Fig. 1). Among these 294 pa-
tients, the cases of 45 patients were complicated with
other connective tissue diseases including 21 rheumatoid
arthritis, 6 lupus erythematosus, 4 systemic sclerosis, 4
Graves’ disease, 2 multiple sclerosis, 2 mixed connective
tissue disease, 1 polymyositis, 1 aortitis syndrome and 1
polyarteritis nodosa.
The study was conducted in accordance with the human
experimental guidelines of our institution and was ap-
proved by the Institutional Review Board of Nagasaki
University. Regarding the handling of patient data that
were obtained before the acquisition of written informed
consent, we present a brief overview of our study on a
Nagasaki University Hospital website in accord with clin-
ical study guidelines issued by our hospital. These records
of patients before acquisition of written informed consent
were anonymized prior to analysis. The division of en-
rolled patients according to the AECG classification cri-
teria is summarized in Fig. 1. The diagnosis of HAM was
determined by the criteria published by Osame et al. [15].
Serological tests and exocrine dysfunction
Detailed explanations of the serological tests and exocrine
dysfunction evaluation are described in our previous pa-
pers [10, 14]. Briefly, antibodies to SS-A/Ro and SS-B/La
antigens were each measured by an enzyme-linked im-
munosorbent assay (ELISA) (Mesacup SS-A/Ro test, nor-
mal range: 10–30 and Mesacup SS-B/La test, normal
range: 15–25; MBL, Nagoya, Japan). With respect to
screening for anti-HTLV-I antibodies, we performed an
ELISA or particle agglutination assay (Serodia-ATL kit,
Eisai, Tokyo). As of 1996, a chemiluminescent enzyme im-
munoassay (normal range: 1.0 cutoff index; Fujirebio,
Tokyo) was used.
For the confirmation of HTLV-I infection among
the HTLV-I-seropositive patients, an immunoblotting
kit (Problot-HTLV-I, Fujirebio) that included HTLV-I
antigens such as three gag proteins and 1 env protein
was used. To measure the patients’ tears and saliva
secretion, Schirmer’s test and the Saxon test were
performed. In the AECG classification criteria, un-
stimulated saliva is used. Instead of the unstimulated
saliva volume, we used the Saxon test. Results from
the sialography were assessed by using the classifica-
tion determined by Rubin and Holt [16].
Minor labial salivary gland biopsy and sialography
Each MSGB biopsy was performed to obtain labial
salivary glands under a local anesthetic. The grading
Fig. 1 Patients with suspected SS who underwent a minor salivary
gland biopsy (MSGB). All patients who underwent an MSGB were
divided into subgroups according to the revised classification criteria
determined by the American European Consensus Group (AECG). SS:
Sjögren’s syndrome, AC: HTLV-I asymptomatic carrier. Shaded
squares indicate the patients with SS
Nakamura et al. BMC Musculoskeletal Disorders  (2015) 16:335 Page 2 of 7
of MNC infiltration in the salivary glands was defined
by Chisholm and Mason [17]. The appearance of at
least one focus of MNCs in 4-mm2 sections was
defined as grade 3. The focus score (FS) was deter-
mined as described by Greenspan et al. [18]. Sialogra-
phy was performed by the insertion of a catheter into
Stensen’s duct [19]. After that, a contrast fluid was
slowly injected into the Stensen’s duct, followed by
image detection.
Statistical analysis
For the comparison of background information and clin-
ical characteristics of the enrolled patients, Welch’s t-test
or Fisher’s exact probability test was used. Fisher’s exact
probability test was also used for the comparison of ob-
jective items in the AECG classification criteria accord-
ing to MSGB grading. For the statistical analysis for the
dot plot of FS values, Mann-Whitney’s U-test was used.
P-values <0.05 were accepted as significant. Interquartile
ranges (IQRs) were also calculated for the FS dot plot.
These analyses were exploratory in nature, and no ad-
justment for multiple testing was applied.
Results
Prevalence of SS in HTLV-I-seropositive subjects according
to the AECG classification criteria
We divided the 294 enrolled patients whose anti-HTLV-
I antibody data were available into the 78 HTLV-I-
seropositive and 216 HTLV-I-seronegative patients. The
patients were also separated into SS and non-SS patients
according to the AECG classification criteria. Forty-five
HTLV-I-seropositive and 125 HTLV-I-seronegative pa-
tients were confirmed to have SS, and thus 26.5 % of the
170 patients with SS were HTLV-I-seropositive. In
addition, among the 26 patients with HAM, 10 patients
(38.5 %) were classified as having SS.
Background elements according to the AECG
classification criteria for HTLV-I-seropositive and -sero-
negative patients with SS
We divided the enrolled SS patients into three
groups: HAM patients with SS, asymptomatic HTLV-
I carriers (AC) with SS, and HTLV-I-seronegative pa-
tients with SS (Table 1). The prevalence of ANA as
well as anti-SS-A/Ro or SS-B/La antibody among the
HAM + SS patients was lower than those among the
AC + SS patients or the HTLV-I-seronegative patients
with SS. However, the prevalence of these antibodies
was not significantly different between the AC + SS
patients and the HTLV-I-seronegative patients with
SS. Contrarily, the prevalence of ocular signs among
the HAM + SS patients was significantly higher than
that among the HTLV-I-seronegative patients with
SS. A similar tendency was also found in the com-
parison with the AC + SS patients. The prevalence of
the ANA centromere pattern was significantly
Table 1 Clinical characteristics of Sjögren’s syndrome (SS) with HAM, whole HAM, SS with asymptomatic carrier and
HTLV-I-seronegative SS
HAM + SS
(n = 10) (A)
AC + SS
(n = 35) (B)
SS negative for
anti-HTLV-I Ab







Age (yrs mean ± SD) 64.0 ± 9.8 61.8 ± 12.4 58.1 ± 13.0 0.279 0.049 0.064
Sex (M/F) 0/10 4/31 4/12 0.311 0.725 0.055
Dry eye (%) 8/10 (80.0) 23/33 (69.7) 79/120 (65.8) 0.421 0.296 0.423
Dry mouth (%) 7/10 (70.0) 29/33 (87.9) 101/123 (82.1) 0.96 0.908 0.309
MSGB grade 3 (%) 6/10 (60.0) 14/35 (40.0) 44/125 (35.2) 0.223 0.102 0.37
MSGB grade 4 (%) 4/10 (40.0) 19/35 (54.3) 69/125 (55.2) 0.331 0.274 0.615
Anti-nuclear antibody (%) 4/10 (40.0) 29/35 (82.9) 110/125 (88.0) 0.013 <0.001 0.859
Centromere pattern in
positive ANA (%)
0/4 (0.0) 2/29 (6.9) 28/110 (25.4) 0.769 0.318 0.021
Anti-SS-A/Ro or SS-B/La
antibody (%)
3/10 (30.0) 23/35 (65.7) 88/125 (70.4) 0.044 0.014 0.772
Rheumatoid factor (%) 3/5 (60.0) 12/24 (50.0) 48/90 (53.3) 0.535 0.57 0.952
Serum IgG (mg/dL;
mean ± SD)
2349.2 ± 1015.5 2164.5 ± 1056.2 1922.3 ± 751.4 0.32 0.124 0.113
Schirmer’s test or Rose-Bengal
test/Fluorescein (%)
9/10 (90.0) 28/31 (90.3) 69/115 (60.0) 0.754 0.055 <0.001
Saxon test or sialography (%) 8/10 (80.0) 26/30 (86.7) 101/116 (87.1) 0.847 0.866 0.656
Results from the minor labial salivary gland biopsy were determined as described by Chisholm & Mason [17]. The presence of at least one focus consisting of
mononuclear cell aggregation was determined as grade 3. The p-values were calculated by Welch’s t-test or Fisher’s exact probability test. MSGB: minor salivary
gland biopsy
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different between the AC + SS patients and the
HTLV-I-seronegative patients with SS.
Differences in the focus scores of MSGB specimens
among the HTLV-I-seropositive and -seronegative patients
with SS
The degree of MNC infiltration determined by
MSGB is illustrated in Fig. 2 by the plot of FS values
of the three patient groups. The FS values of the
HAM + SS patients (median [IQR] = 1.0 [1.0–3.5])
were not significantly different from those of the
AC + SS patients (median [IQR] = 1.0 [1.0–3.0]) or
the HTLV-I-seronegative patients with SS (median
[IQR] = 2.0 [1.0–3.0]).
The prevalence of the objective items in the MSGB-
positive patients with SS
Lastly, we compared the prevalence of four objective items
in the cases that were MSGB-positive in the AECG classi-
fication criteria among the three groups with patients with
SS (Fig. 3). There was no significant difference among the
Saxon test and Schirmer’s test results among the groups.
The prevalence of ANA among the HAM + SS pa-
tients was significantly lower than those of the AC + SS
patients and the HTLV-seronegative patients with SS
(p < 0.001). In addition, the prevalence of anti-SS-A/Ro
or SS-B/La antibody among the HAM + SS patients
was significantly lower than that of the HTLV-
seronegative patients with SS (p = 0.013), and there
was a tendency for this tendency to be lower compared
with the AC + SS patients (p = 0.061) The prevalences
were determined by Fisher’s exact probability test.
Classification of SS in the patients with HAM according to
the AECG criteria and the preliminary classification
criteria
With regard to the 10 HAM patients who were classified
as having SS, their profiles based on the AECG classifi-
cation criteria are shown in Table 2. All 10 patients also
fulfilled the preliminary classification criteria. With re-
spect to the AECG classification criteria, seven patients
fulfilled four items, two patients fulfilled five items, and
one patient fulfilled six items. As shown in Table 1, the
positive rate of anti-SS-A/Ro or SS-B/La antibody was 3
of these 10 patients (30.0 %).
Discussion
After Green et al. [20] demonstrated in 1989 that
HTLV-I tax transgenic mice showed SS-like sialadenitis,
the association between HTLV-I and SS was studied.
Epidemiological studies by Nagasaki [6, 21] showed dis-
tinct evidence with regard to the involvement of HTLV-I
in SS as one of the environmental factors. In our studies
of complications of SS in HAM patients [10, 14], we
used the preliminary criteria [11] released in 1993. Al-
though in the preliminary criteria four of the six items
are required to classify SS, there was no limitation re-
garding which four items.
The clinical and pathological manifestations of the
HTLV-I-seropositive patients with SS according to the
AECG classification criteria are presented herein. In
Fig. 1, the prevalence of HTLV-I among the confirmed
SS patients was 45 of 170 (26.4 %). Since it is known that
approx. 1 % of the entire population of Japan has anti-
HTLV-I antibody [22, 23], the 26.5 % seropositivity in
the present study’s SS patients is thought to be higher
than that of the Japanese general population. In this re-
gard, we should emphasize that the enrolled patients in
this study are considerably different from the general
population. We should also note that the enrolled sub-
jects were suspected of having SS and that the classifica-
tion of the enrolled subjects was based on salivary gland
biopsies, indicating that this biased classification influ-
ences the interpretation of the present data.
The prevalence of ANA and anti-SS-A/Ro or SS-B/La
antibodies determined by the AECG classification
Fig. 2 Distribution of focus scores (FS) among the three patient
groups. The MSGB focus scores were determined by the method of
Greenspan et al. [18]. The presence of at least one focus consisting
of mononuclear cell (MNC) aggregation was determined as grade 3.
Bars indicate the median value of each column. The significance of
differences was calculated by Mann-Whitney’s U-test. NS; not significant
AC: HTLV-I asymptomatic carrier
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criteria was significantly low in the present population’s
HAM+ SS patients compared to the AC + SS patients
and the HTLV-I-seronegative patients with SS, which is in
accord with the results [10, 14] determined by the prelim-
inary classification criteria. Contrarily, the prevalence of
ocular signs including Schirmer’s test or staining tests in
the HAM+ SS patients was higher than that in the
HTLV-I-seronegative patients with SS. These results sug-
gest that HAM patients with SS have a high prevalence of
ocular inflammation and a low prevalence of serological
abnormalities.
With regard to the prevalence of SS among patients
with HAM, our 2000 study revealed that the cases of 13
of 20 patients with HAM (65 %) were complicated with
SS according to the preliminary classification criteria
[14]. There is a tendency for a difference (p = 0.068 de-
termined by Fisher’s exact probability test) between the
65 % we reported in 2000 and the 38.5 % we observed in
the present 2015 study (i.e., among the 26 patients with
HAM, 10 patients [38.5 %] were classified as having SS);
however, this difference is not significant even though
there is a 15-year difference in the dates of the two stud-
ies and differences in the classification approach.
The degree of cell infiltration into minor salivary
glands (MSGs) determined by the FS established by
Greenspan et al. [18] was equally high in the present
HAM+ SS patients compared to that in the AC + SS pa-
tients and the HTLV-I-seronegative patients with SS. As
far as the positive MSGB cases were concerned, a low
prevalence of ANA and a low prevalence of anti-SS-A/
Ro or SS-B/La antibody were observed in the HAM+ SS
patients. Although the pathogenesis of SS found in pa-
tients with HAM remains unclear, both the preliminary
and AECG classification criteria demonstrated similar
clinical and serological findings. In our previous study
[24], the prevalence of ectopic germinal center (GC) for-
mation along with CXC chemokine ligand-13 (CXCL13)
was low in HTLV-I-seropositive patients with SS, espe-
cially in HAM patients with SS, indicating that the low
prevalence of serology in the present study might be
Fig. 3 Prevalence of objective items in SS patients with grades 3 or 4 among the four patient groups. The prevalence of each item was
determined by Chisholm & Mason grading [17]. The presence of at least one focus consisting of MNC aggregation was determined as grade 3.
The positive rate of four objective items is shown. The significance of differences was assessed using Fisher’s exact probability test.
(*p < 0.05 vs. HAM + SS, **p < 0.01 vs. HAM + SS) AC: HTLV-I asymptomatic carrier, ANA: anti-nuclear antibody
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explained by a low prevalence of GCs and CXCL13, be-
cause CXCL13 in GCs is an important factor to attract
B cells [25, 26] that differentiate into plasma cells and
produce autoantibodies such as anti-SS-A/Ro antibody.
Taken together, the past and present findings show that
the AECG classification criteria resulted in clinical and
pathological features that were similar to those obtained
by using the preliminary classification criteria for HTLV-I-
seropositive patients with SS. Even though the criteria
were revised, our results showed that the HTLV-I-
seropositive patients with SS (including HAM patients
with SS) had an unwavering tendency with respect to
clinicopathological findings.
Conclusions
Because we have only fragmentary findings [24, 27] with
regard to the pathogenesis of HTLV-I-seropositive pa-
tients with SS, a molecular biological approach is neces-
sary to verify the findings obtained in this retrospective
study. As a future evaluation, a prospective cohort study
including an SS disease activity index such as the Euro-
pean League Against Rheumatism (EULAR) SS disease
activity index (ESSDAI) or the EULAR SS patient-
reported index (ESSPRI) [28, 29] is required to specific-
ally determine whether HTLV-I is a risk factor of SS and
to establish the accurate disease activity of HTLV-I-
seropositive patients with SS. As an animal model
shows SS-like sialadenitis [20], HTLV-I may be
implicated in the pathogenesis of SS. The exclusion of
HTLV-I infection from the classification criteria might
be considered in the future because human immuno-
deficiency virus and hepatitis type C infection are also
excluded from the AECG and ACR classification
criteria.
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